Mitoxantrone targets human ubiquitin-specific peptidase 11 (USP11) and is a potent inhibitor of pancreatic cancer cell survival

Richard A. Burkhart, Yu Peng, Zoë A. Norris, Renée M. Tholey, Vanessa A. Talbott, Qin Liang, Yongxing Ai, Kathy Miller, Shruti Lal, Joseph A. Cozzitorto, Agnieska K. Witkiewicz, Charles J. Yeo, Matthew Gehrmann, Andrew Napper, Jordan M. Winter, Janet A. Sawicki, Zhihao Zhuang, Jonathan R. Brody

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Pancreatic ductal adenocarcinoma (PDA) is the fourth leading cause of cancer-related death in the United States, with a 95% five-year mortality rate. For over a decade, gemcitabine (GEM) has been the established first-line treatment for this disease despite suboptimal response rates. The development of PARP inhibitors that target the DNA damage repair (DDR) system in PDA cells has generated encouraging results. Ubiquitinspecific peptidase 11 (USP11), an enzyme that interacts with the DDR protein BRCA2, was recently discovered to play a key role in DNA double-strand break repair and may be a novel therapeutic target. A systematic high-throughput approach was used to biochemically screen 2,000 U.S. Food and Drug Administration (FDA)-approved compounds for inhibition of USP11 enzymatic activity. Six pharmacologically active small molecules that inhibit USP11 enzymatic activity were identified. An in vitro drug sensitivity assay demonstrated that one of these USP11 inhibitors, mitoxantrone, impacted PDA cell survival with an IC50 of less than 10 nM. Importantly, across six different PDA cell lines, two with defects in the Fanconi anemia/ BRCA2 pathway (Hs766T and Capan-1), mitoxantrone is 40- to 20,000-fold more potent than GEM, with increased endogenous USP11 mRNA levels associated with increased sensitivity to mitoxantrone. Interestingly, USP11 silencing in PDA cells also enhanced sensitivity to GEM. These findings establish a preclinical model for the rapid discovery of FDA-approved compounds and identify USP11 as a target of mitoxantrone in PDA. Implications: This high-throughput approach provides a strong rationale to study mitoxantrone in an early-phase clinical setting for the treatment of PDA.

Original languageEnglish (US)
Pages (from-to)901-911
Number of pages11
JournalMolecular Cancer Research
Volume11
Issue number8
DOIs
StatePublished - Aug 2013

Fingerprint

Mitoxantrone
Ubiquitin
Pancreatic Neoplasms
gemcitabine
Cell Survival
Adenocarcinoma
Peptide Hydrolases
United States Food and Drug Administration
DNA Repair
DNA Damage
BRCA2 Protein
Fanconi Anemia
Double-Stranded DNA Breaks
Protease Inhibitors
Inhibitory Concentration 50
Cell Line
Messenger RNA
Mortality
Enzymes
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Molecular Biology
  • Cancer Research
  • Oncology

Cite this

Mitoxantrone targets human ubiquitin-specific peptidase 11 (USP11) and is a potent inhibitor of pancreatic cancer cell survival. / Burkhart, Richard A.; Peng, Yu; Norris, Zoë A.; Tholey, Renée M.; Talbott, Vanessa A.; Liang, Qin; Ai, Yongxing; Miller, Kathy; Lal, Shruti; Cozzitorto, Joseph A.; Witkiewicz, Agnieska K.; Yeo, Charles J.; Gehrmann, Matthew; Napper, Andrew; Winter, Jordan M.; Sawicki, Janet A.; Zhuang, Zhihao; Brody, Jonathan R.

In: Molecular Cancer Research, Vol. 11, No. 8, 08.2013, p. 901-911.

Research output: Contribution to journalArticle

Burkhart, RA, Peng, Y, Norris, ZA, Tholey, RM, Talbott, VA, Liang, Q, Ai, Y, Miller, K, Lal, S, Cozzitorto, JA, Witkiewicz, AK, Yeo, CJ, Gehrmann, M, Napper, A, Winter, JM, Sawicki, JA, Zhuang, Z & Brody, JR 2013, 'Mitoxantrone targets human ubiquitin-specific peptidase 11 (USP11) and is a potent inhibitor of pancreatic cancer cell survival', Molecular Cancer Research, vol. 11, no. 8, pp. 901-911. https://doi.org/10.1158/1541-7786.MCR-12-0699
Burkhart, Richard A. ; Peng, Yu ; Norris, Zoë A. ; Tholey, Renée M. ; Talbott, Vanessa A. ; Liang, Qin ; Ai, Yongxing ; Miller, Kathy ; Lal, Shruti ; Cozzitorto, Joseph A. ; Witkiewicz, Agnieska K. ; Yeo, Charles J. ; Gehrmann, Matthew ; Napper, Andrew ; Winter, Jordan M. ; Sawicki, Janet A. ; Zhuang, Zhihao ; Brody, Jonathan R. / Mitoxantrone targets human ubiquitin-specific peptidase 11 (USP11) and is a potent inhibitor of pancreatic cancer cell survival. In: Molecular Cancer Research. 2013 ; Vol. 11, No. 8. pp. 901-911.
@article{b98d04c10afd425caa98f110eed20153,
title = "Mitoxantrone targets human ubiquitin-specific peptidase 11 (USP11) and is a potent inhibitor of pancreatic cancer cell survival",
abstract = "Pancreatic ductal adenocarcinoma (PDA) is the fourth leading cause of cancer-related death in the United States, with a 95{\%} five-year mortality rate. For over a decade, gemcitabine (GEM) has been the established first-line treatment for this disease despite suboptimal response rates. The development of PARP inhibitors that target the DNA damage repair (DDR) system in PDA cells has generated encouraging results. Ubiquitinspecific peptidase 11 (USP11), an enzyme that interacts with the DDR protein BRCA2, was recently discovered to play a key role in DNA double-strand break repair and may be a novel therapeutic target. A systematic high-throughput approach was used to biochemically screen 2,000 U.S. Food and Drug Administration (FDA)-approved compounds for inhibition of USP11 enzymatic activity. Six pharmacologically active small molecules that inhibit USP11 enzymatic activity were identified. An in vitro drug sensitivity assay demonstrated that one of these USP11 inhibitors, mitoxantrone, impacted PDA cell survival with an IC50 of less than 10 nM. Importantly, across six different PDA cell lines, two with defects in the Fanconi anemia/ BRCA2 pathway (Hs766T and Capan-1), mitoxantrone is 40- to 20,000-fold more potent than GEM, with increased endogenous USP11 mRNA levels associated with increased sensitivity to mitoxantrone. Interestingly, USP11 silencing in PDA cells also enhanced sensitivity to GEM. These findings establish a preclinical model for the rapid discovery of FDA-approved compounds and identify USP11 as a target of mitoxantrone in PDA. Implications: This high-throughput approach provides a strong rationale to study mitoxantrone in an early-phase clinical setting for the treatment of PDA.",
author = "Burkhart, {Richard A.} and Yu Peng and Norris, {Zo{\"e} A.} and Tholey, {Ren{\'e}e M.} and Talbott, {Vanessa A.} and Qin Liang and Yongxing Ai and Kathy Miller and Shruti Lal and Cozzitorto, {Joseph A.} and Witkiewicz, {Agnieska K.} and Yeo, {Charles J.} and Matthew Gehrmann and Andrew Napper and Winter, {Jordan M.} and Sawicki, {Janet A.} and Zhihao Zhuang and Brody, {Jonathan R.}",
year = "2013",
month = "8",
doi = "10.1158/1541-7786.MCR-12-0699",
language = "English (US)",
volume = "11",
pages = "901--911",
journal = "Molecular Cancer Research",
issn = "1541-7786",
publisher = "American Association for Cancer Research Inc.",
number = "8",

}

TY - JOUR

T1 - Mitoxantrone targets human ubiquitin-specific peptidase 11 (USP11) and is a potent inhibitor of pancreatic cancer cell survival

AU - Burkhart, Richard A.

AU - Peng, Yu

AU - Norris, Zoë A.

AU - Tholey, Renée M.

AU - Talbott, Vanessa A.

AU - Liang, Qin

AU - Ai, Yongxing

AU - Miller, Kathy

AU - Lal, Shruti

AU - Cozzitorto, Joseph A.

AU - Witkiewicz, Agnieska K.

AU - Yeo, Charles J.

AU - Gehrmann, Matthew

AU - Napper, Andrew

AU - Winter, Jordan M.

AU - Sawicki, Janet A.

AU - Zhuang, Zhihao

AU - Brody, Jonathan R.

PY - 2013/8

Y1 - 2013/8

N2 - Pancreatic ductal adenocarcinoma (PDA) is the fourth leading cause of cancer-related death in the United States, with a 95% five-year mortality rate. For over a decade, gemcitabine (GEM) has been the established first-line treatment for this disease despite suboptimal response rates. The development of PARP inhibitors that target the DNA damage repair (DDR) system in PDA cells has generated encouraging results. Ubiquitinspecific peptidase 11 (USP11), an enzyme that interacts with the DDR protein BRCA2, was recently discovered to play a key role in DNA double-strand break repair and may be a novel therapeutic target. A systematic high-throughput approach was used to biochemically screen 2,000 U.S. Food and Drug Administration (FDA)-approved compounds for inhibition of USP11 enzymatic activity. Six pharmacologically active small molecules that inhibit USP11 enzymatic activity were identified. An in vitro drug sensitivity assay demonstrated that one of these USP11 inhibitors, mitoxantrone, impacted PDA cell survival with an IC50 of less than 10 nM. Importantly, across six different PDA cell lines, two with defects in the Fanconi anemia/ BRCA2 pathway (Hs766T and Capan-1), mitoxantrone is 40- to 20,000-fold more potent than GEM, with increased endogenous USP11 mRNA levels associated with increased sensitivity to mitoxantrone. Interestingly, USP11 silencing in PDA cells also enhanced sensitivity to GEM. These findings establish a preclinical model for the rapid discovery of FDA-approved compounds and identify USP11 as a target of mitoxantrone in PDA. Implications: This high-throughput approach provides a strong rationale to study mitoxantrone in an early-phase clinical setting for the treatment of PDA.

AB - Pancreatic ductal adenocarcinoma (PDA) is the fourth leading cause of cancer-related death in the United States, with a 95% five-year mortality rate. For over a decade, gemcitabine (GEM) has been the established first-line treatment for this disease despite suboptimal response rates. The development of PARP inhibitors that target the DNA damage repair (DDR) system in PDA cells has generated encouraging results. Ubiquitinspecific peptidase 11 (USP11), an enzyme that interacts with the DDR protein BRCA2, was recently discovered to play a key role in DNA double-strand break repair and may be a novel therapeutic target. A systematic high-throughput approach was used to biochemically screen 2,000 U.S. Food and Drug Administration (FDA)-approved compounds for inhibition of USP11 enzymatic activity. Six pharmacologically active small molecules that inhibit USP11 enzymatic activity were identified. An in vitro drug sensitivity assay demonstrated that one of these USP11 inhibitors, mitoxantrone, impacted PDA cell survival with an IC50 of less than 10 nM. Importantly, across six different PDA cell lines, two with defects in the Fanconi anemia/ BRCA2 pathway (Hs766T and Capan-1), mitoxantrone is 40- to 20,000-fold more potent than GEM, with increased endogenous USP11 mRNA levels associated with increased sensitivity to mitoxantrone. Interestingly, USP11 silencing in PDA cells also enhanced sensitivity to GEM. These findings establish a preclinical model for the rapid discovery of FDA-approved compounds and identify USP11 as a target of mitoxantrone in PDA. Implications: This high-throughput approach provides a strong rationale to study mitoxantrone in an early-phase clinical setting for the treatment of PDA.

UR - http://www.scopus.com/inward/record.url?scp=84882800748&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84882800748&partnerID=8YFLogxK

U2 - 10.1158/1541-7786.MCR-12-0699

DO - 10.1158/1541-7786.MCR-12-0699

M3 - Article

C2 - 23696131

AN - SCOPUS:84882800748

VL - 11

SP - 901

EP - 911

JO - Molecular Cancer Research

JF - Molecular Cancer Research

SN - 1541-7786

IS - 8

ER -